2 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Molybdenum Cofactor Deficiency, Complementation Group A: new trials by email Literature Review of Molybdenum Cofactor Deficiency, Complementation Group A trials Research Report on Molybdenum Cofactor Deficiency, Complementation Group A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A ORGN001 (formerly ALXN1101) - Molybdenum Cofactor Deficiency, Type A | Phase 2 / Phase 3 | Completed | Origin Biosciences | 5 | 2016-05-01 | 2023-10-17 |
| Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP ORGN001 (formerly ALXN1101) - Molybdenum Cofactor Deficiency, Type A | Phase 2 | Completed | Origin Biosciences | 8 | 2014-04-01 | 2023-10-17 |
| Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A cPMP - Molybdenum Cofactor Deficiency Type A | Phase 1 / Phase 2 | Withdrawn | Orphatech Pharmaceuticals, GmbH | 10 | 2009-08-01 | 2011-02-01 |
Molybdenum cofactor deficiency (2)
molybdopterin synthase (1) · nulibry (1)
Origin Biosciences (2) · Orphatech Pharmaceuticals, GmbH (1)
Australia (2) · United Kingdom (2) · United States (2) · Israel (1) · Netherlands (1) · Norway (1) · Spain (1) · Tunisia (1) · Turkey (Türkiye) (1)
Alex Veldman, MD (1) · Liza Squires, M.D. (1)